Addex Therapeutics (ADXN) Stock Forecast, Price Target & Predictions
ADXN Stock Forecast
Addex Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a 211.20% upside from ADXN’s last price of $9.64) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
ADXN Price Target
The average price target for Addex Therapeutics (ADXN) is $30.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 211.20% upside from ADXN's last price of $9.64.
ADXN Analyst Ratings
According to 1 Wall Street analysts, Addex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ADXN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Addex Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Raghuram Selvaraju | H.C. Wainwright | $30.00 | $10.52 | 185.11% | 211.20% |
The latest Addex Therapeutics stock forecast, released on Aug 28, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $30.00, which represents a 185.11% increase from the stock price at the time of the forecast ($10.52), and a 211.20% increase from ADXN last price ($9.64).
Addex Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $30.00 | $30.00 | $30.00 |
| Last Closing Price | $9.64 | $9.64 | $9.64 |
| Upside/Downside | 211.20% | 211.20% | 211.20% |
In the current month, the average price target of Addex Therapeutics stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 211.20% increase as opposed to Addex Therapeutics's last price of $9.64. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Addex Therapeutics's last stock rating was published by H.C. Wainwright on Aug 28, 2024. The company gave ADXN a "Buy" rating, the same as its previous rate.
Addex Therapeutics Financial Forecast
Addex Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $500.89K | $592.43K | $409.42K | $183.35K | $237.24K | $397.49K | $682.00K | $992.60K | $844.22K |
| Avg Forecast | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $213.50K | $698.73K | $660.97K | $607.13K | $277.19K | $283.21K | $238.34K | $228.63K | $508.13K | $505.57K | $515.01K | $414.32K | $258.15K | $765.86K |
| High Forecast | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $213.50K | $698.73K | $660.97K | $607.13K | $277.19K | $283.21K | $238.34K | $228.63K | $508.13K | $505.57K | $515.01K | $414.32K | $258.15K | $765.86K |
| Low Forecast | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $201.62K | $213.50K | $698.73K | $660.97K | $607.13K | $277.19K | $283.21K | $238.34K | $228.63K | $508.13K | $505.57K | $515.01K | $414.32K | $258.15K | $765.86K |
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.77% | 2.49% | 1.79% | 0.36% | 0.47% | 0.77% | 1.65% | 3.85% | 1.10% |
Addex Therapeutics's average Quarter revenue forecast for Jun 23 based on 0 analysts is $277.19K, with a low forecast of $277.19K, and a high forecast of $277.19K. ADXN's average Quarter revenue forecast represents a -44.66% decrease compared to the company's last Quarter revenue of $500.89K (Mar 23).
Addex Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-2.30M | $-3.40M | $-4.09M | $-7.01M | $-5.68M | $-4.33M | $-3.50M | $-4.58M | $-2.53M |
| Avg Forecast | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-213.50K | $-698.73K | $-660.97K | $-607.13K | $-277.19K | $-283.21K | $-238.34K | $-3.79M | $-508.13K | $-3.78M | $-436.24K | $-3.50M | $-3.73M | $-648.72K |
| High Forecast | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-213.50K | $-698.73K | $-660.97K | $-607.13K | $-277.19K | $-283.21K | $-238.34K | $-3.03M | $-508.13K | $-3.02M | $-436.24K | $-2.80M | $-2.99M | $-648.72K |
| Low Forecast | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-201.62K | $-213.50K | $-698.73K | $-660.97K | $-607.13K | $-277.19K | $-283.21K | $-238.34K | $-4.55M | $-508.13K | $-4.54M | $-436.24K | $-4.20M | $-4.48M | $-648.72K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.12% | 14.25% | 1.08% | 13.79% | 1.50% | 9.93% | 1.00% | 1.23% | 3.90% |
undefined analysts predict ADXN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Addex Therapeutics's previous annual EBITDA (undefined) of $NaN.
Addex Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-2.43M | $-3.82M | $-4.05M | $-7.35M | $-5.88M | $-4.43M | $-3.60M | $-4.69M | $-2.64M |
| Avg Forecast | $-117.99M | $-117.99M | $-117.99M | $-353.96M | $-117.99M | $-117.99M | $-124.94M | $-38.94M | $-55.26M | $-59.22M | $-72.10M | $-92.08M | $-92.99M | $-3.90M | $-252.66M | $-3.88M | $-917.13M | $-3.60M | $-3.82M | $-955.66M |
| High Forecast | $-117.99M | $-117.99M | $-117.99M | $-353.96M | $-117.99M | $-117.99M | $-124.94M | $-38.94M | $-55.26M | $-59.22M | $-72.10M | $-92.08M | $-92.99M | $-3.12M | $-252.66M | $-3.10M | $-917.13M | $-2.88M | $-3.06M | $-955.66M |
| Low Forecast | $-117.99M | $-117.99M | $-117.99M | $-353.96M | $-117.99M | $-117.99M | $-124.94M | $-38.94M | $-55.26M | $-59.22M | $-72.10M | $-92.08M | $-92.99M | $-4.68M | $-252.66M | $-4.65M | $-917.13M | $-4.32M | $-4.59M | $-955.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 0.04% | 1.04% | 0.03% | 1.52% | 0.00% | 1.00% | 1.23% | 0.00% |
Addex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADXN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Addex Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $1.80M | $-240.68K | $2.39M | $1.53M | $2.24M | $497.58K | $1.47M | $1.85M | $1.32M |
| Avg Forecast | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $611.83K | $2.00M | $1.89M | $1.74M | $794.35K | $811.61K | $683.02K | $655.20K | $1.46M | $1.08M | $1.10M | $881.86K | $549.45K | $1.63M |
| High Forecast | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $611.83K | $2.00M | $1.89M | $1.74M | $794.35K | $811.61K | $683.02K | $655.20K | $1.46M | $1.08M | $1.10M | $881.86K | $549.45K | $1.63M |
| Low Forecast | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $577.77K | $611.83K | $2.00M | $1.89M | $1.74M | $794.35K | $811.61K | $683.02K | $655.20K | $1.46M | $1.08M | $1.10M | $881.86K | $549.45K | $1.63M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 2.22% | -0.35% | 3.65% | 1.05% | 2.08% | 0.45% | 1.67% | 3.36% | 0.81% |
Addex Therapeutics's average Quarter SG&A projection for Jun 23 is $794.35K, based on 0 Wall Street analysts, with a range of $794.35K to $794.35K. The forecast indicates a -55.91% fall compared to ADXN last annual SG&A of $1.80M (Mar 23).
Addex Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.24 | $-0.51 | $-0.51 | $-1.18 | $-0.93 | $-0.78 | $-0.66 | $-0.84 | $-0.48 |
| Avg Forecast | $-1.21 | $-1.21 | $-1.21 | $-3.63 | $-1.21 | $-1.21 | $-1.28 | $-0.40 | $-0.57 | $-0.61 | $-0.74 | $-0.94 | $-0.95 | $-1.83 | $-2.59 | $-9.56 | $-11.87 | $-15.87 | $-14.53 | $-12.37 |
| High Forecast | $-1.21 | $-1.21 | $-1.21 | $-3.63 | $-1.21 | $-1.21 | $-1.28 | $-0.40 | $-0.57 | $-0.61 | $-0.74 | $-0.94 | $-0.95 | $-1.83 | $-2.59 | $-9.56 | $-11.87 | $-15.87 | $-14.53 | $-12.37 |
| Low Forecast | $-1.21 | $-1.21 | $-1.21 | $-3.63 | $-1.21 | $-1.21 | $-1.28 | $-0.40 | $-0.57 | $-0.61 | $-0.74 | $-0.94 | $-0.95 | $-1.83 | $-2.59 | $-9.56 | $-11.87 | $-15.87 | $-14.53 | $-12.37 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 0.53% | 0.28% | 0.46% | 0.10% | 0.07% | 0.04% | 0.06% | 0.04% |
According to undefined Wall Street analysts, Addex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADXN previous annual EPS of $NaN (undefined).
Addex Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| IPHA | Innate Pharma | $2.26 | $10.00 | 342.48% | Buy |
| ATXI | Avenue Therapeutics | $2.81 | $12.00 | 327.05% | Buy |
| ADXN | Addex Therapeutics | $9.64 | $30.00 | 211.20% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
ADXN Forecast FAQ
Is Addex Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Addex Therapeutics (ADXN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ADXN's total ratings.
What is ADXN's price target?
Addex Therapeutics (ADXN) average price target is $30 with a range of $30 to $30, implying a 211.20% from its last price of $9.64. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Addex Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ADXN stock, the company can go up by 211.20% (from the last price of $9.64 to the average price target of $30), up by 211.20% based on the highest stock price target, and up by 211.20% based on the lowest stock price target.
Can Addex Therapeutics stock reach $14?
ADXN's average twelve months analyst stock price target of $30 supports the claim that Addex Therapeutics can reach $14 in the near future.
What is Addex Therapeutics's current price target trend?
1 Wall Street analyst forecast a $30 price target for Addex Therapeutics (ADXN) this month, up 211.20% from its last price of $9.64. Compared to the last 3 and 12 months, the average price target increased by 211.20% and increased by 211.20%, respectively.
What are Addex Therapeutics's analysts' financial forecasts?
Addex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.32M (high $1.32M, low $1.32M), average EBITDA is $-1.315M (high $-1.315M, low $-1.315M), average net income is $-400M (high $-400M, low $-400M), average SG&A $3.77M (high $3.77M, low $3.77M), and average EPS is $-4.1 (high $-4.1, low $-4.1). ADXN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $806.46K (high $806.46K, low $806.46K), average EBITDA is $-806K (high $-806K, low $-806K), average net income is $-708M (high $-708M, low $-708M), average SG&A $2.31M (high $2.31M, low $2.31M), and average EPS is $-7.258 (high $-7.258, low $-7.258).
Did the ADXN's actual financial results beat the analysts' financial forecasts?
Based on Addex Therapeutics's last annual report (Dec 2022), the company's revenue was $1.42M, which missed the average analysts forecast of $1.48M by -3.93%. Apple's EBITDA was $-20.168M, beating the average prediction of $-8.32M by 142.39%. The company's net income was $-21.069M, missing the average estimation of $-353M by -94.04%. Apple's SG&A was $7.3M, beating the average forecast of $3.87M by 88.60%. Lastly, the company's EPS was $-2.8, missing the average prediction of $-14.93 by -81.25%. In terms of the last quarterly report (Mar 2023), Addex Therapeutics's revenue was $500.89K, beating the average analysts' forecast of $283.22K by 76.86%. The company's EBITDA was $-2.3M, beating the average prediction of $-283K by 712.07%. Addex Therapeutics's net income was $-2.433M, missing the average estimation of $-92.079M by -97.36%. The company's SG&A was $1.8M, beating the average forecast of $811.61K by 121.96%. Lastly, the company's EPS was $-0.24, missing the average prediction of $-0.944 by -74.58%